Description

Technical Parameters

Cardiogen 20mg/bottle core introduction

Pharmaceutical-grade peptide formulations | Made in China, heart regeneration and repair peptides 20mg/bottle

Specifications : 20mg/bottle, 5 bottles/box

Purity : ≥99% (HPLC detection)

Appearance : White lyophilized powder

Storage : Store frozen at -20℃ away from light; after thawing, refrigerate at 2-8℃.

Core advantages and functions

Cardiogen is a bioactive peptide that targets myocardial repair and regeneration . By specifically activating myocardial cell survival pathways, promoting angiogenesis, and inhibiting myocardial fibrosis , it has important application value in the treatment of cardiovascular diseases, myocardial repair, and cardiac regenerative medicine , and is a key tool for cardiovascular research and regenerative medicine .

✅Heart repair mechanism :

Cardiovascular protection : Activation of PI3K/Akt and ERK1/2 survival signaling pathways

Angiogenesis : Promotes the proliferation and migration of vascular endothelial cells

Anti-fibrotic : Inhibits the activation and transformation of myocardial fibroblasts

Anti-apoptosis : Reduces ischemia/reperfusion injury of cardiomyocytes

Metabolic regulation : Improves myocardial energy metabolism and mitochondrial function

✅Quality advantages of Chinese manufacturers :

Sequence Design : Active Fragments Based on Key Growth Factors for Heart Development

Synthesis process : Fmoc solid-state synthesis combined with microwave-assisted technology

Purification control : Preparative HPLC + ion exchange chromatography, purity ≥ 99.5%

Activity validation : Dual validation using in vitro cardiomyocyte model and in vivo myocardial infarction model.

Aseptic production : Class C cleanroom, fully automated filling and freeze-drying system

Quality Control Documents : Provide complete quality study documents (CMC document package).

✅Product Features :

Cardiac targeting : has natural targeting properties for myocardial tissue

High stability : Stability is enhanced by D-amino acid and PEGylation modification.

High safety profile : Preclinical safety studies show a wide therapeutic window.

Synergistic effect : Can be used in combination with stem cells, exosomes, etc.

Usage and Storage Guide

1. Reconstitution and preparation :

Solvent selection :

First choice: Sterile saline

In vitro study: serum-free DMEM medium

Special application: PBS buffer containing 0.1% BSA

Standard configuration :

Inject 1 mL of solvent into the 20 mg vial and gently swirl to dissolve.

A stock solution of 20 mg/mL was obtained .

Gradually dilute to the working concentration using the appropriate solvent.

Dissolution control :

Dissolution conditions: Dissolve at room temperature in the dark for 5-10 minutes.

Solution properties: Clear and transparent, without precipitate.

pH requirement: Final pH 6.8-7.4

Contraindications: Avoid violent shaking and ultrasonic treatment.

2. Storage conditions :

Unopened :

Freeze at -20℃: Can be stored for 24 months

-80℃ deep freeze: can be stored for 36 months

Avoid repeated freeze-thaw cycles (recommended ≤3 times).

Reconstituted :

Stock solution: Stable for 5 days when refrigerated at 4°C.

Working solution: It is recommended to prepare and use immediately , and keep at 4°C for no more than 24 hours.

Store in smaller containers: Can be stored at -20℃ for 1 month.

Transportation conditions :

Dry ice transport (below -78℃)

Use professional deep-freezing transport boxes

Equipped with a temperature recorder for full monitoring

Stability parameters :

Temperature sensitivity: Degradation is accelerated at temperatures above 37℃.

pH stability: 6.8-7.4 is optimal.

Photosensitivity: Sensitive to ultraviolet light, requires handling in the absence of light.

Oxidation sensitivity: Avoid contact with oxidants

3. Research and application plan :

In vitro cell experiments :

Cell model :

Rat cardiomyocytes (H9c2)

Human cardiomyocytes (AC16)

Primary cardiomyocytes

Cardiac fibroblasts

Vascular endothelial cells (HUVECs)

Concentration gradient :

Low concentration: 0.1-1 nM

Medium concentration: 1-10 nM

High concentration: 10-100 nM

Processing time :

Short-term: 5 minutes to 6 hours (signal path)

Mid-term: 12-48 hours (gene expression)

Long-term: 72-120 hours (functional testing)

Evaluation indicators :

Cell viability: CCK-8, MTT

Apoptosis detection: Annexin V/PI, TUNEL

Functional assessment: calcium transients, contractile function

Molecular mechanisms: Western blot, qPCR, immunofluorescence

Animal in vivo studies :

Disease model :

Myocardial infarction model: Ligation of the left anterior descending artery

ischemia/reperfusion injury model

Cardiomyopathy model: Doxorubicin induction

Heart failure model: aortic coarctation

Route of administration :

Intramyocardial injection: 20-50 μg/point per injection , multiple injection points.

Intravenous injection: 0.5-2.0 mg/kg , once daily.

Intraperitoneal injection: 0.2-1.0 mg/kg , once daily.

Intracardiac injection: 10-20 μg/animal , single dose

Dosage regimen :

Acute phase treatment: Administer medication immediately after model establishment, for 7 consecutive days.

Chronic phase treatment: Begin after model establishment and continue for 4-8 weeks.

Preventive treatment: Begins 1 week before modeling.

Monitoring indicators :

Cardiac function: echocardiography, cardiac catheterization

Hemodynamics: Blood pressure, heart rate, cardiac output

Histology: Masson staining, WGA staining

Molecular biology: Western blot, qPCR

Vascular density: CD31 immunohistochemistry

Mechanism of action study :

Signal paths: PI3K/Akt, ERK1/2, STAT3

Autophagy regulation: LC3, p62, Beclin-1

Mitochondrial functions: membrane potential, ROS production

Metabolomics: Analysis of Energy Metabolites

4. Experimental Design Suggestions :

Dosage exploration :

Low dose: 0.1 mg/kg

Medium dose: 0.5 mg/kg

High dose: 2.0 mg/kg

Control group setup :

Blank control: physiological saline

Model control: Myocardial infarction + solvent

Positive control: Angiotensin-converting enzyme inhibitor

Time point design :

Acute phase: 1-7 days after administration

Subacute phase: 2-4 weeks

Chronic phase: 4-8 weeks

Detection method :

Echocardiography: LVEF, LVFS, LVID

Hemodynamics: Left ventricular pressure-volume loop

Histopathology: infarct area, fibrosis area

Molecular detection: Western blot, qPCR

Sample collection :

Blood: Separation of serum for detection of myocardial enzymes

Heart tissue: fixed with 4% paraformaldehyde/frozen in liquid nitrogen

Cardiac cells: collagenase perfusion isolation

Why choose Cardiogen, made in China?

Technical advantages :

Autonomous design capability of cardiovascular bioactive peptides

Advanced targeted modification and delivery technologies

A comprehensive in vitro-in vivo efficacy evaluation platform

Professional pharmacokinetic research capabilities

Quality Guarantee :

Strict raw material control: monitoring the entire process from starting materials to finished products.

Advanced analytical equipment: UPLC-MS/MS, CD, NMR, etc.

Complete stability study: accelerated and long-term stability data

Batch consistency: Quality variation controlled within ±5%

Service Support :

Professional technical support team

For detailed experimental protocol reference

Literature support and research consultation

Customized peptide modification services

Respond quickly to customer needs

Cost -effectiveness :

Large-scale production reduces unit costs

Prices are 30-50% lower than similar imported products.

Flexible packaging options

Bulk order discounts

Research and application directions

Cardiovascular disease research :

Myocardial protection after myocardial infarction

Pathological mechanisms of heart failure

Reversal strategies for myocardial hypertrophy

Prevention and treatment of myocardial fibrosis

Regenerative medicine :

Optimization of cardiac stem cell therapy

Heart tissue engineering

Cell transplantation adjuvant therapy

Molecular mechanisms of cardiac regeneration

Translational medicine :

New cardiovascular drug development

Exploring combination therapy strategies

Drug delivery system optimization

Preclinical safety evaluation

Basic research :

Molecular mechanisms of heart development

Cardiac cell signal transduction

Regulatory mechanisms of angiogenesis

Research on cardiac metabolism

Summarize

Cardiogen represents a significant achievement for China in the research and development of peptide drugs for cardiovascular regenerative medicine . Through innovative sequence design, rigorous manufacturing processes, and systematic pharmacological validation , it provides cardiovascular disease researchers worldwide with a high-quality, highly active research tool . This product has significant application value in the study of myocardial repair mechanisms and the development of cardiovascular drugs , and is expected to drive the advancement of the cardiovascular regenerative medicine field.

Technical Support and Ordering :

We provide comprehensive technical support services, including:

Detailed technical documents and quality certificates

Experimental design and optimization suggestions

Literature search and research progress updates

Peptide modification, labeling, and customization services

Technical training and experimental guidance

Customized services for bulk orders

Need anything, please contact us